No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
NEW INDICATION ALERT – FDA Approves Takeda’s ENTYVIO® (vedolizumab) for Crohn’s Maintenance
On 18 April 2024, Takeda announced FDA approval of subcutaneous administration of ENTYVIO® (vedolizumab) for maintaining therapy in adults with moderately to severely active Crohn’s disease (CD). This follows the FDA's acceptance of Takeda's BLA for ENTYVIO® for the...